June 1, 2026 – Type 1 Diabetes TrialNet (TrialNet), the world’s leading international research network dedicated to the prevention of type 1 diabetes, today announced the appointment of Michael Haller, MD, as Chair and Carmella Evans-Molina, MD, PhD, as Vice Chair.

A new clinical study is testing rezpegaldesleukin to see if it can help people recently diagnosed with type 1 diabetes continue to make insulin by resetting the body's natural immune balance. Rezpegaldesleukin has already shown promising results in clinical trials for other autoimmune diseases, including atopic dermatitis and lupus.

As we begin a new year, we are excited to share TrialNet’s progress in 2025 and our plans for the year ahead.

We also want to take this opportunity to thank our participants, their families, and our research teams. Your commitment helps us learn more about how T1D progresses and contributes to advances in preventing and delaying type 1 diabetes (T1D).

From camper to director of the largest camping association serving people with diabetes

When Lisa Gier attended her first diabetes camp at Camp Hodia (a mix of Idaho and diabetes) at age 10, she had no idea she would build an amazing career in camping.

As we begin a new year, it’s the perfect time to celebrate our accomplishments. We recently spoke with TrialNet Chair Kevan Herold, MD, to get his insights on the past year and plans for the year ahead. Dr. Herold is a professor of immunobiology and medicine at Yale University, one of 17 TrialNet Clinical Centers at the forefront of type 1 diabetes research.

More than a quarter million people screened for risk

TrialNet Chair Kevan C. Herold, MD, Yale University, reflects on key accomplishments of the past year and shares direction for 2024 and beyond.

Dear TrialNet family,

As we start the new year, I want to take time to recognize TrialNet’s major achievements in 2023 and share our direction for advancing type 1 diabetes (T1D) research in the year ahead.

DECA Executive Director Terry Ackley, and his wife, Carol, volunteered at Camp Seale Harris for several years before he was hired as the Camp’s executive director in 1995. He served in that role until joining DECA in 2012. Pictured here: Terry and Carol (right) with daughter, Emily (left), son-in-law, Patrick, and granddaughter, Vivienne.

TrialNet Chair Kevan C. Herold, MD, reflects on advances in type 1 diabetes research and the need to continue testing promising treatments.

Dear TrialNet Family,

Landmark findings from TrialNet research were instrumental in the Food and Drug Administration’s (FDA) November 17, 2022 approval of the first drug to delay type 1 diabetes (T1D) in people at risk.

TrialNet conducted the clinical study that discovered the immunotherapy drug teplizumab could delay T1D for 2+ years.